GlassScriptPhysician profile
Rick G Hummel
NPI 1609955483
$12,283.52
in general payments reported to CMS, 2019-2025
59 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $1,334 · 2021: $1,985 · 2022: $1,194 · 2023: $1,796 · 2024: $1,820 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,929 · Education: $43.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,929.37 |
| Education | $43.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $972.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $830.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $821.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $802.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $735.03 | 2020-2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $686.48 | 2023-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $660.95 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Jazz Pharmaceuticals INC. | $650.63 | 2024-2025 | |
| Novo Nordisk INC | $570.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Emd Serono, INC. | $557.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $454.13 | 2019-2025 | Xifaxan |
| Abbvie INC. | $417.24 | 2020-2025 | |
| Pfizer INC. | $397.63 | 2019-2025 | |
| Mylan Specialty L.P. | $370.53 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $309.01 | 2019-2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Hummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.